All In Biotech

Drug Trial Radar · NCT06155422

A Prospective Real-world Study of Cadonilimab in Patients With Recurrent or Metastatic Cervical Cancer

Efficacy and Safety of Cadonilimab (PD-1/CTLA-4 Bispecific Antibody) in the Treatment of Recurrent or Metastatic Cervical Cancer: a Multicenter, Prospective, Real-world Study

Last checked: Nov 20, 2026Latest source record: Dec 4, 2023 (this record)Source: ClinicalTrials.govMethods & limitations

Not yet recruiting

Status

Not yet recruiting

Enrollment

670

Planned (sponsor's estimate)

Start

Nov 30, 2023

Primary completion

Nov 30, 2026

Study completion Nov 30, 2027

Sponsor

Lead sponsor
Gang Chen (101199)Academic, hospital or other
Sponsor type
Academic, hospital or other
First posted
Dec 4, 2023

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
No
Who can join
Female only, from 18 years, up to 90 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This real-world study included all patients with recurrent or metastatic cervical cancer who used Cadonilimab in clinical practice, regardless of treatment lines and combination with different treatments. Through follow-up observations, the aim of this study is to analyze the efficacy of Cadonilimab for recurrent or metastatic cervical cancer in the real world, and to explore the differences in the efficacy of Cadonilimab in different stages of treatment, as well as the efficacy of different treatment combinations, so as to provide clinical evidence for the use of Cadonilimab for recurrent or metastatic cervical cancer.

Conditions

  • Recurrent or Metastatic Cervical Cancer

Interventions

  • CadonilimabDrug

    recurrent or metastatic cervical cancer in the first, second or third lines Systematic treatment

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Objective response rate (ORR)Time frame: from the first drug administration up to two years

Locations

No sites are listed on the registry yet.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.